Mumbai: Sun Pharmaceutical Industries Limited has introduced that one in all its wholly-owned subsidiaries has launched Palbociclib, a novel anti-cancer drug, in India for sufferers who’ve superior breast cancer. The firm will make the drug accessible below the model title PALENOTM (Palbociclib) 75 mg, 100 mg, and 125 mg.

Breast most cancers is the commonest type of most cancers in India, affecting roughly 0.21 million new feminine sufferers yearly. Among the whole sufferers, roughly 50 per cent of instances are of hormone receptor-positive breast most cancers, the key subtype of breast most cancers. Though hormone receptor-positive breast most cancers sufferers have proven higher survival than different subtypes, they might progress to or current with metastatic illness.

Palbociclib has been accepted by the USFDA, EMA and CDSCO, together with hormonal therapies for sufferers with hormone receptor-positive, human epidermal development issue receptor 2-negative regionally superior or metastatic breast most cancers.

Commenting on the launch, Kirti Ganorkar, CEO, India Business, Sun Pharma, mentioned “We are introducing Palbociclib at an affordable price which will help improve patient access. PALENOTM will address the treatment needs of advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance program that will improve patient compliance and accessibility.”